Clinical trials: Hemorrhagic Stroke
- Condition Hemorrhagic Stroke
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hemorrhagic Stroke, Ischemic Stroke
Early Feasibility Study of the SENSE Device
A single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset.
- Trial name
- NCT03827720
- Testing
- SENSE Device
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sense Diagnostics, LLC
Stroke, Acute Stroke
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT07751328
- Testing
- Axana Scan and MRI
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wellumio R&D Australia Pty Ltd
Hemorrhage
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
This study is designed to validate implementation of the CRI algorithm in the CypherOx CRI system. Healthy human subjects will undergo progressive reduction in central blood volume to the point of hemodynamic instability (defined…
- Trial name
- NCT01935427
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Flashback Technologies
Stroke, Acute, Intracranial Hemorrhages
Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet
The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects.
- Trial name
- NCT03495206
- Testing
- Y-2(Edaravone And Borneol) Sublingual Tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yantai YenePharma Co., Ltd.